Craig Campbell

List of Publications by Year
in descending order

57 papers	3,089 citations	279798 23 h-index	161849 54 g-index
60 all docs	60 docs citations	60 times ranked	3877 citing authors

#	Article	IF	Citations
1	Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. New England Journal of Medicine, 2018, 378, 625-635.	27.0	977
2	Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 390, 1489-1498.	13.7	365
3	Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle and Nerve, 2014, 50, 477-487.	2.2	357
4	Myostatin inhibitor ACEâ€031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placeboâ€controlled clinical trial. Muscle and Nerve, 2017, 55, 458-464.	2.2	176
5	The TREAT-NMD Duchenne Muscular Dystrophy Registries: Conception, Design, and Utilization by Industry and Academia. Human Mutation, 2013, 34, 1449-1457.	2.5	94
6	Treating pediatric neuromuscular disorders: The future is now. American Journal of Medical Genetics, Part A, 2018, 176, 804-841.	1.2	93
7	Congenital Myotonic Dystrophy: Assisted Ventilation Duration and Outcome. Pediatrics, 2004, 113, 811-816.	2.1	76
8	Infantile muscular dystrophy in Canadian aboriginals is an Î±Bâ€crystallinopathy. Annals of Neurology, 2011, 69, 866-871.	5.3	62
9	Congenital Myotonic Dystrophy: Canadian Population-Based Surveillance Study. Journal of Pediatrics, 2013, 163, 120-125.e3.	1.8	57
10	Developing standardized corticosteroid treatment for Duchenne muscular dystrophy. Contemporary Clinical Trials, 2017, 58, 34-39.	1.8	56
11	Deflazacort for the treatment of Duchenne Dystrophy: A systematic review. BMC Neurology, 2003, 3, 7.	1.8	50
12	Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy. JAMA - Journal of the American Medical Association, 2022, 327, 1456.	7.4	43
13	Subacute Sclerosing Panencephalitis: Results of the Canadian Paediatric Surveillance Program and review of the literature. BMC Pediatrics, 2005, 5, 47.	1.7	41
14	Parentâ€reported multiâ€national study of the impact of congenital and childhood onset myotonic dystrophy. Developmental Medicine and Child Neurology, 2016, 58, 698-705.	2.1	41
15	Meta-analyses of ataluren randomized controlled trials in nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2020, 9, 973-984.	1.4	41
16	Randomized phase 2 trial and open-label extension of domagrozumab in Duchenne muscular dystrophy. Neuromuscular Disorders, 2020, 30, 492-502.	0.6	40
17	Disease burden and functional outcomes in congenital myotonic dystrophy. Neurology, 2016, 87, 160-167.	1.1	33
18	Consensus-based care recommendations for congenital and childhood-onset myotonic dystrophy type 1. Neurology: Clinical Practice, 2019, 9, 443-454.	1.6	32

#	Article	IF	Citations
19	Seizures Related to Hypomagnesemia. Child Neurology Open, 2016, 3, 2329048X1667483.	1.1	29
20	Factors Associated With Health-Related Quality of Life in Children With Duchenne Muscular Dystrophy. Journal of Child Neurology, 2016, 31, 879-886.	1.4	28
21	Reldesemtiv in Patients with Spinal Muscular Atrophy: a Phase 2 Hypothesis-Generating Study. Neurotherapeutics, 2021, 18, 1127-1136.	4.4	28
22	Duchenne Muscular Dystrophy: Canadian Paediatric Neuromuscular Physicians Survey. Canadian Journal of Neurological Sciences, 2010, 37, 195-205.	0.5	27
23	Symptomatic dystrophinopathies in female children. Neuromuscular Disorders, 2011, 21, 172-177.	0.6	27
24	Pharmacological therapy for the prevention and management of cardiomyopathy in Duchenne muscular dystrophy: A systematic review. Neuromuscular Disorders, 2017, 27, 4-14.	0.6	23
25	Orofacial strength, dysarthria, and dysphagia in congenital myotonic dystrophy. Muscle and Nerve, 2018, 58, 413-417.	2.2	20
26	Fatigue in young people with Duchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2020, 62, 245-251.	2.1	19
27	Newborn Screening for Spinal Muscular Atrophy: Ontario Testing and Follow-up Recommendations. Canadian Journal of Neurological Sciences, 2021, 48, 504-511.	0.5	18
28	The CNDR: Collaborating to Translate New Therapies for Canadians. Canadian Journal of Neurological Sciences, 2013, 40, 698-704.	0.5	16
29	Congenital myotonic dystrophy in a national registry. Paediatrics and Child Health, 2010, 15, 514-518.	0.6	15
30	Physical function and mobility in children with congenital myotonic dystrophy. Muscle and Nerve, 2017, 56, 224-229.	2.2	14
31	Health-Related Quality of Life in Children with Duchenne Muscular Dystrophy: A Review. Journal of Neuromuscular Diseases, 2015, 2, 313-324.	2.6	13
32	The relationship between quality of life and healthâ€related quality of life in young males with Duchenne muscular dystrophy. Developmental Medicine and Child Neurology, 2017, 59, 1152-1157.	2.1	13
33	Prenatal, Neonatal, and Early Childhood Features in Congenital Myotonic Dystrophy. Journal of Neuromuscular Diseases, 2018, 5, 331-340.	2.6	13
34	The Canadian Neuromuscular Disease Registry: Connecting patients to national and international research opportunities. Paediatrics and Child Health, 2018, 23, 20-26.	0.6	11
35	Further delineation of TBCK - Infantile hypotonia with psychomotor retardation and characteristic facies type 3. European Journal of Medical Genetics, 2019, 62, 273-277.	1.3	11
36	Twinkle-Associated Mitochondrial DNA Depletion. Pediatric Neurology, 2019, 90, 61-65.	2.1	11

#	Article	IF	Citations
37	Myotonic dystrophy type 1. Cmaj, 2016, 188, 1033-1033.	2.0	10
38	An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries. Orphanet Journal of Rare Diseases, 2022, 17, 113.	2.7	9
39	Patientâ€reported study of the impact of pediatricâ€onset myotonic dystrophy. Muscle and Nerve, 2019, 60, 392-399.	2.2	8
40	Routine lung volume recruitment in boys with Duchenne muscular dystrophy: a randomised clinical trial. Thorax, 2022, 77, 805-811.	5.6	8
41	Randomized phase 2 study of <scp>ACE</scp>â€083, a <scp>muscleâ€promoting</scp> agent, in facioscapulohumeral muscular dystrophy. Muscle and Nerve, 2022, 66, 50-62.	2.2	8
42	Developmental Milestones and Quality of Life Assessment in a Congenital Myotonic Dystrophy Cohort. Journal of Neuromuscular Diseases, 2016, 3, 405-412.	2.6	7
43	We need a â€œmade in Canadaâ€•orphan drug framework. Cmaj, 2017, 189, E1274-E1275.	2.0	7
44	Ontario Newborn Screening for Spinal Muscular Atrophy: The First Year. Canadian Journal of Neurological Sciences, 2022, 49, 821-823.	0.5	7
45	Distal arthrogryposis type 5 and PIEZO2 novel variant in a Canadian family. American Journal of Medical Genetics, Part A, 2019, 179, 1034-1041.	1.2	6
46	A National Spinal Muscular Atrophy Registry for Real-World Evidence. Canadian Journal of Neurological Sciences, 2020, 47, 810-815.	0.5	6
47	Meta-analyses of deflazacort versus prednisone/prednisolone in patients with nonsense mutation Duchenne muscular dystrophy. Journal of Comparative Effectiveness Research, 2021, 10, 1337-1347.	1.4	6
48	<scp>12â€Month</scp> progression of motor and functional outcomes in congenital myotonic dystrophy. Muscle and Nerve, 2021, 63, 384-391.	2.2	5
49	Health related quality of life in young, steroid-naÃ¯ve boys with Duchenne muscular dystrophy. Neuromuscular Disorders, 2021, 31, 1161-1168.	0.6	4
50	Agitated behavior scale in pediatric traumatic brain injury. Brain Injury, 2019, 33, 916-921.	1.2	3
51	Î±â€tropomyosin gene (TPM3) mutation in an infant with nemaline myopathy. Clinical Case Reports (discontinued), 2021, 9, 1672-1676.	0.5	3
52	The Effect of Noninvasive Positive Pressure Ventilation on Pneumonia Hospitalizations in Children With Neurological Disease. Child Neurology Open, 2017, 4, 2329048X1668902.	1.1	2
53	A Phenotypic Description of Congenital Myotonic Dystrophy using PhenoStacks. Journal of Neuromuscular Diseases, 2019, 6, 341-347.	2.6	2
54	Body composition in patients with congenital myotonic dystrophy. Muscle and Nerve, 2019, 60, 176-179.	2.2	2

#	Article	IF	Citations
55	Drisapersen associated with elevated serum factor VIII levels in Duchenne muscular dystrophy. Neurology, 2020, 94, 538-540.	1.1	2
56	Case 2: Chronic daily headache in a teenager. Paediatrics and Child Health, 2010, 15, 263-266.	0.6	1
57	Magnetic Resonance Imaging Findings Are Associated with Long-Term Global Neurological Function or Death after Traumatic Brain Injury in Critically Ill Children. Journal of Neurotrauma, 2021, 38, 2407-2418.	3.4	1